Researchers from the Boston University School of Public Health in the United States say there is no evidence to support a correlation between ABO blood group and the risk of infection with severe ...
CAMBRIDGE, Mass., July 30, 2025 (GLOBE NEWSWIRE) -- Arbor Biotechnologies, Inc., a biotechnology company discovering and developing the next generation of genetic medicines, today announced the first ...
NEW YORK and CLEVELAND, Nov. 17, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that information about the ...
- ABO-101 was well tolerated with no serious adverse events or dose-limiting toxicities reported in the 28-days following dosing - Phase 1/2 redePHine study (NCT06839235) dose escalation ongoing with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback